HARBIN, China, April 21 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced it had commenced the commercial launch of Oxymetazoline Hydrochloride Nasal Drops and Moschus Liniment for Pain Relief.
Oxymetazoline Hydrochloride Nasal Drops, a generic drug, is to treat acute and chronic rhinitis, sinusitis and allergic rhinitis. Moschus Liniment for Pain Relief is a TCM product developed in-house, which is used to relieve the pain from scathe, wound, rheumatism and arthrosis.
The two products, quite reliable and convenient for consumers' use, are estimated to have a market size of over $300 million each. The Company will analyze and summarize the marketing and sales activities following the trial stage and establish a formal sales plan soon.
"We are happy to add two new products to our sales mix and anticipate they will contribute roughly $1.0 million to our total revenues in 2010," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. "We continue our efforts to commercialize 11 additional drugs in our R&D pipeline in order to support sustainable, long term growth."
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio-Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.cski.com.cn .
Safe Harbor Statement
Certain of the statements made in the press release constitute
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include the commercial launch of Oxymetazoline Hydrochloride Nasal Drops and Moschus Liniment for Pain Relief. Actual results could differ materially from the expectations reflected in such
forward-looking statements as a result of a variety of factors, including the risks associated with the ability to launch new products, market acceptance of new product launches, the effect of changing economic conditions in The People's Republic of China, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
For more information, please contact:
Company Contact:
China Sky One Medical, Inc.
Mr. Stanley Hao, CFO
Tel: +86-451-8703-2617
Email: stanleyhao@cski.com.cn
Investor Relations Contact:
CCG Investor Relations
Ms. Lei Huang, Account Manager
Tel: +1-646-833-3417
Email: lei.huang@ccgir.com
Web: http://www.ccgirasia.com
Ms. Mabel Zhang, Vice President
Tel: +1-310-954-1353
Email: mabel.zhang@ccgir.com
